Angiogenesis is a process by which neo-vessels are formed from pre-existing ones. Although it is a physiological and fundamental process, especially in embryogenesis and reproduction, persistent angiogenesis plays an important role in the progression of certain pathological conditions, including malignant solid tumors. Recent studies reveal that tumor angiogenesis is indispensable for the growth of primary tumors, as well as distant metastasis. [1] [2] [3] Thus, angiogenesis has become an important subject in the research field of oncology.
Angiogenesis is thought to be controlled by the balance between angiogenic factors and angiogenesis inhibitors. A number of angiogenic factors have been identified to date, and basic fibroblast growth factor (bFGF) and vascular endothelial growth factor (VEGF) are recognized as representative angiogenic factors among them. 4, 5) VEGF is a specific mitogen for endothelial cells (ECs), and plays important roles in both physiological and pathological angiogenesis. 6, 7) In contrast, bFGF affects a broad spectrum of cell types including ECs. 2, 8) Although bFGF is not involved in the physiological angiogenic process of vascular development in the embryo, it is thought to play an important role in tumor angiogenesis. 9, 10) bFGF stimulates proliferation and migration of ECs, and also induces the transcription factor ETS-1, urokinase-type plasminogen activator (u-PA), and matrix metalloproteinase (MMP-1) in, and tube formation by, these cells. 11) However, the precise signal transduction system in ECs in relation to bFGF effects is ill-defined.
Members of the MAP kinase family, namely, extracellular signal-regulated kinase (ERK) 1/2, c-Jun N-terminal kinase (JNK) 1, and p38 MAP kinase, are central elements of post-receptor signal transduction pathways in mammalian cells including Ecs.
12) It is generally considered that growth factors primarily stimulate the ERK pathway, whereas many stress-related signals stimulate JNK and/or p38 MAP kinase pathways. 13) It has been reported that bFGF activates ERK1/2 in cells 14, 15) and that the ERK1/2 activation regulates the cell proliferation that is requisite for angiogenesis. p38 MAP kinase is involved in modulating the migration of human umbilical vein endothelial cells (HUVECs) through actin reorganization. 16) In the present study, we investigated the roles of ERK1/ 2 and p38 MAP kinase in the signal transduction of bFGF effects in a murine endothelial cell line, MSS31. Our results indicate that both ERK1/2 and p38 MAP kinase are required for the signals of bFGF in angiogenesis. Although the roles of these two MAP kinases are not identical, they work in a coordinated fashion.
MATERIALS AND METHODS
Reagents Anti-JNK1 and anti-p38 MAP kinase antibodies and GST-ATF-2 (1-96) were purchased from Santa Cruz Biotechnology (Santa Cruz, CA); and myelin basic protein (MBP) and heat shock protein 25 18) and grown in α-minimum essential medium (MEM) supplemented with 10% fetal calf serum (FCS) (Summit Biotechnology, Ft. Collins, CO) and 100 µg/ml kanamycin. Determination of ERK1/2 activity ERK1/2 activity was determined by an in-gel kinase assay as described. 19) Briefly, cells were extracted with lysis buffer (10 mM TrisCl [pH 7.5], 1% Triton X-100, 0.15 M NaCl, 1 mM EDTA, 50 mM NaF, 5 mM β-glycerophosphate, 1 mM Na 3 VO 4 , 2 mM phenylmethylsulfonyl fluoride). Samples containing equal amounts of protein were eluted in 4× sodium dodecyl sulfate (SDS) sample buffer and subjected to 10% SDS-polyacrylamide gel electrophoresis (PAGE) with 0.25 mg/ml MBP co-polymerized in the gel under reducing conditions. After electrophoresis, the gel was P]ATP) at room temperature for 1 h. Finally, the gel was washed with 5% trichloroacetic acid and 1% sodium pyrophosphate at room temperature several times, followed by drying and autoradiography. Determination of JNK1, p38 MAP kinase, and MAP-KAP kinase-2 activities JNK1, p38 MAP kinase, and MAPKAP kinase-2 activities were determined by an immune-complex kinase as described. 19) Briefly, cells were extracted in the same way as described for the in-gel kinase assay. For determination of JNK1 activity, cell lysates were incubated at 4°C overnight with 1 µg of rabbit antibody that recognizes the carboxyl terminus of human and murine JNK1. This was followed by the addition of protein A Sepharose 4 Fast Flow (Pharmacia Biotech AB, Uppsala, Sweden) and incubation for 1 h at 4°C. The resultant precipitates were washed 4 times with lysis buffer, and then twice with kinase buffer (20 
Tube formation by MSS31 cells in type I collagen gel
Tube formation by MSS31 cells in type I collagen gel was examined as described. 11) Briefly, MSS31 cells were seeded onto the surface of type I collagen gel (Nitta Gelatin, Osaka). After having reached confluence, the monolayers were incubated in α-MEM containing 1% FCS and 0.1% DMSO, PD98059 or SB203580 for 60 min; then human recombinant bFGF was added to a final concentration of 1 nM. After a 6-day incubation, tube-like structures formed in the gel were measured in terms of total tube length/field (×200) with NIH image software. DNA synthesis DNA synthesis was analyzed with cell proliferation ELISA/5-bromo-2′-deoxyuridine (BrdU)-chemiluminescence (Boehringer Mannheim, Mannheim, Germany) according to the manufacturer's protocol. Briefly, MSS31 cells were seeded into 96-well microtiter plates, cultured in α-MEM containing 10% FCS for 24 h, washed with phosphate-buffered saline (PBS) and serumfree medium, and cultured with α-MEM containing 0.1% FCS for a further 24 h. After preincubation with 0.1% dimethyl sulfoxide (DMSO), PD98059 or SB203580, the medium was replaced with that containing bFGF for stimulation and BrdU was added simultaneously. After a 24-h incubation, the cells were fixed. Peroxidase (POD)-conjugated anti-BrdU antibody was then added and incorporated BrdU was measured by chemiluminescence. Cell migration Cell migration was examined by wound migration assay as previously described.
11) Briefly, confluent cultures were preincubated with 0.1% DMSO, PD98059 or SB203580 for 60 min and wounded with a razor blade. The cellular debris was subsequently removed by washing with PBS. The monolayers were incubated in α-MEM containing 0.1% FCS and 0.1% DMSO, PD98059 or SB203580, with or without 1 nM bFGF. After a 24-h incubation, the number of cells that had migrated across the edge of the wound was counted under ×100 magnification. Fluorescence staining of F-actin and vinculin Cells were fixed with 3.7% formaldehyde in PBS for 30 min at room temperature and then treated with 0.1% Nonidet P-40 in PBS for 10 min. Nonspecific staining was blocked by incubating cells with 5% skim milk in PBS and normal goat serum. After the cells had been incubated with monoclonal anti-vinculin antibody (Seikagaku Co., Tokyo) for 60 min at room temperature, fluorescein-conjugated goat anti-mouse IgG (Jackson ImmunoResearch Laboratories, West Grove, PA) and rhodamine-conjugated phalloidin (Molecular Probes, Eugene, OR) were applied to them, and incubation was carried out for 30 min at 37°C. Cells were mounted and microscopic observation was done with an LSM410 Laser Scan Microscope (Carl Zeiss, Jena, Germany). Northern blot analysis Confluent monolayers of MSS31 cells in 60-mm plastic dishes were preincubated for 16 h in α-MEM containing 1% FCS, and then human recombinant bFGF was added. After incubation for 2 h, total RNA was extracted from the monolayers with ISOGEN (Nippon Gene Co., Ltd., Tokyo) used according to the manufacturer's protocol. Northern blotting was performed as described. 19) In brief, equal amounts of total RNA were loaded onto 1% agarose gel containing 2.2 M formaldehyde, electrophoresed, and transferred to a Hybond N + filter (Amersham Life Sciences Inc.). The filter was hybridized with 32 P-labeled probe in hybridization solution overnight at 42°C. The filter was washed in 2× SSC/0.1% SDS at room temperature and then in 0.2× SSC/0.1% SDS at 65°C. Autoradiography was carried out with an imaging plate and analyzed with a BAS2000 Image Analyzer (Fuji, Tokyo). Murine ets-1 cDNA template (737 bps) was prepared by reverse-transcriptional PCR using the following primer pairs: sense, 5′-CCCTGGGTAAAGAATGCTT-TCTCG-3′; antisense, 5′-GGACTGACAAGACTTATCA-GTGAG-3′. Calculations and statistical analysis The statistical significance of differences in the results was evaluated by use of unpaired ANOVA, and P values were calculated by Fisher's PLSD.
RESULTS
bFGF activates ERK1/2, JNK1, and p38 MAP kinase in MSS31 cells The activation of three MAP kinases, ERK1/2, JNK1, and p38 MAP kinase, in MSS31 after treatment with bFGF was analyzed. The in-gel kinase assay with MBP as a substrate showed activation of ERK1 (p44 MAP kinase) and ERK2 (p42 MAP kinase) with peaks of 35.0 and 10.3 fold activation, respectively, at 10 min, which levels gradually declined to 18.3 and 4.6 fold activation at 60 min (Fig. 1A) . JNK1 and p38 MAP kinase activations were measured by the immune-complex kinase assay with GST-c-Jun (1-79) and GST-ATF-2 (1-96), respectively, as substrates. bFGF induced the activation of JNK1 and p38 MAP kinase with peaks of 4.1 and 2.2 fold activation, respectively, at 10 min (Fig. 1, B and C) . The activation of p38 MAP kinase was transient, as the activity returned to the basal level by 30 min (Fig. 1C) . PD98059 and SB203580 inhibit ERK1/2 and p38 MAP kinase of MSS31 cells in a specific manner To clarify the roles of MAP kinases in the signal transduction of bFGF effects in ECs, we employed two specific inhibitors. PD98059 is a specific inhibitor of MEK1, 20) an upstream element of ERK1/2, and SB203580 is a specific inhibitor of p38 MAP kinase.
21) The specificity of these two inhibitors in our system was shown as follows: PD98059 at the concentration of 50 µM reduced the activation of ERK1/2 by 56%, whereas it did not affect the activation of p38 MAP kinase in ECs after the treatment with bFGF ( Fig.  2A) . SB203580 at the concentration of 10 µM reduced the bFGF-mediated activation of p38 MAP kinase by about 67%, as determined by the activation of MAPKAP kinase- The samples "N10" were harvested, in the same way, at 10 min after the addition of the vehicle without bFGF.
2, a downstream element of p38 MAP kinase, whereas it slightly augmented the activation of ERK1/2 (Fig. 2B) .
Neither of the inhibitors showed any apparent cytotoxic effect in terms of the cellular morphology. PD98059 and SB203580 inhibit bFGF-stimulated tube formation by MSS31 cells To investigate whether ERK1/ 2 and/or p38 MAP kinase activities are required for bFGFmediated angiogenesis, we analyzed tube formation by ECs in type 1 collagen gel. When MSS31 cells were cultured on type 1 collagen gel, they invaded the gel and formed tube-like structures in it. This tube formation by MSS31 cells was enhanced by the treatment with bFGF. In the presence of PD98059 or SB203580, tube formation was inhibited in a dose-dependent manner. PD98059 at the concentration of 50 µM completely inhibited tube formation, whereas inhibition by 10 µM SB203580 was partial but significant (Fig. 3) . These results indicate that the activities of ERK1/2 and p38 MAP kinase are indispensable for angiogenesis.
PD98059 and SB203580 inhibit bFGF-stimulated DNA synthesis of MSS31 cells Angiogenesis is a complex phenomenon that relies on several independent properties of
ECs, including cell proliferation, cell migration, and gene induction. We next examined the effect of these inhibitors on DNA synthesis of MSS31 cells stimulated with bFGF. DNA synthesis was measured by BrdU incorporation as described in "Materials and Methods." PD98059 as well as SB203580 inhibited bFGF-stimulated DNA synthesis in a dose-dependent manner; and 50 µM PD98059 or 10 µM SB203580 reduced it to near the basal level (Fig. 4) . Thus, both ERK1/2 and p38 MAP kinase activities are required for bFGF-stimulated DNA synthesis. PD98059 and SB203580 inhibit bFGF-stimulated migration of MSS31 cells Cell migration was analyzed by the wound migration assay. bFGF stimulated the migration of MSS31 cells. PD98059 as well as SB203580 inhibited bFGF-stimulated cell migration in a dose-dependent manner (Fig. 5) . Thus, both ERK1/2 and p38 MAP kinase activities are required for bFGF-stimulated cell migration. SB203580 inhibits bFGF-stimulated actin reorganization and vinculin assembly of MSS31 cells Since coordinated regulation of actin reorganization and focal adhesion are required for cell migration, 22) we examined whether bFGF and MAP kinases are involved in these two phenomena. MSS31 cells were exposed to bFGF for 24 h. described in "Materials and Methods." bFGF induced actin reorganization, resulting in stress fiber formation. Additionally, vinculin was visualized in both ends of stress fibers in bFGF-treated cells. Though PD98059 at a concentration of 50 µM did not inhibit stress fiber formation or vinculin assembly, SB203580 inhibited these processes at a concentration of 10 µM (Fig. 6) . bFGF-mediated induction of ets-1 mRNA in MSS31 cells is mediated via the activation of ERK1/2 We have previously shown that ETS-1, the prototype of ets family transcription factors, is induced in ECs by angiogenic growth factors, including bFGF. 11) bFGF induced the expression of ets-1 mRNA in MSS31 cells. Though 50 µM PD98059 inhibited ets-1 mRNA induction, SB203580 showed no inhibition, even at 30 µM (Fig. 7) . Thus, the induction of ets-1 mRNA by bFGF in MSS31 cells was preferentially mediated via the ERK1/2 pathway.
DISCUSSION
We have examined the transduction of bFGF-mediated signals in ECs by using a murine EC line, MSS31, as a model. We found that bFGF activated three MAP kinase homologs, ERK1/2, JNK1, and p38 MAP kinase. Among them, ERK1/2 and p38 MAP kinase were found to be indispensable for bFGF-mediated angiogenesis in vitro, i.e., tube formation in type I collagen gel. They appeared to regulate proliferation and migration of, and gene induction in, ECs in a concomitant but coordinated fashion.
bFGF-stimulated DNA synthesis of ECs was inhibited by both PD98059 and SB203580, suggesting both ERK1/2 and p38 MAP kinase activities to be required for bFGFstimulated DNA synthesis. It is generally accepted that the activation of ERK1/2 is required for DNA synthesis in various cell types, 23) and this effect of ERK1/2 is thought to be mediated via the induction of cyclin D1. 24) However, evidence that p38 MAP kinase regulates DNA synthesis is rather sparse. However, recent reports suggest that p38 MAP kinase is involved in the DNA synthesis of certain cell types. 25, 26) p38 MAP kinase is known to phosphorylate a number of transcription factors, resulting in the induction of a number of genes. For example, Elk-1 and ATF-2 are directly phosphorylated by p38 MAP kinase. 27 ) cAMP response element binding protein (CREB), on the other hand, is phosphorylated via MAPKAP kinase-2/3, an immediate downstream kinase of p38 MAP kinase. 28) However, it remains to be elucidated which molecule participates in the p38 MAP kinase-mediated DNA synthesis in ECs.
bFGF-stimulated migration of ECs was inhibited by both PD98059 and SB203580, suggesting that both ERK1/ 2 and p38 MAP kinase activities are required for bFGFstimulated cell migration. Cell migration is a complex phenomenon that requires cytoskeleton-regulated cell motility, as well as cell adhesion. 22) bFGF elicited actin reorganization and the assembly of vinculin in focal adhesion plaques. SB203580 but not PD98059 inhibited these processes, indicating that p38 MAP kinase preferentially regulates these processes. Growth factors such as VEGF and oxidative stress are reported to induce actin reorganization in ECs via the activation of p38 MAP kinase. 16, 29) One of the downstream elements that p38 MAP kinase phophorylates is MAPKAP kinase 2/3, which is a serine/ threonine kinase that has been suggested to play a role in actin reorganization. 30) As PD98059 did not affect actin reorganization or vinculin assembly in bFGF-stimulated ECs, ERK1/2 was suggested to regulate bFGF-stimulated cell migration via a distinct mechanism. The fact that PD98059 but not SB203580 inhibited the induction of ETS-1 in ECs might be responsible for the inhibitory effect of PD98059 on cell migration. Recent work in our laboratory revealed that ETS-1 converts EC to an invasive phenotype by inducing the expression of proteases including u-PA, MMP-1, MMP-3, and MMP-9, as well as integrin β3 subunit as target genes in ECs. 11, 31) u-PA, MMP-1, MMP-3, and MMP-9 are responsible for degradation of extracellular matrices, whereas u-PA 32, 33) and integrin β3 34, 35) are responsible for cell migration. Therefore, the inhibitory effect of PD98059 on cell migration may derive at least in part from the impaired expression of ETS-1 target genes. The 5′ ETS-1 promoter contains Sp1, Ap1, Ap2, and ETS binding sites, 36) and ETS-1 autoinduces the expression of ETS-1 via binding to ETS binding site. 37) Moreover, the Pointed domain within ETS-1, which is homologous to the Drosophila ETS family transcription factor Pointed, contains a target amino acid sequence for MAP kinases including ERK1/2, and once this sequence is phosphorylated, transactivation activity of ETS-1 is markedly enhanced. 38) These findings explain how ERK1/2 enhances the expression of ETS-1 in ECs. We previously reported that ETS-1 was induced in ECs after denuding injury and that this induction of ETS-1 was mediated via p38 MAP kinase, as SB203580 inhibited the induction of ETS-1. 19) The discrepancy of growth factor-mediated and denudationmediated induction of ETS-1 in ECs raises the possibility that distinct sets of p38 MAP zkinase homologs are activated by growth factors and denuding injury. p38 MAP kinase contains 4 isoforms, namely p38α, p38β, p38γ and p38δ, [39] [40] [41] and the functions of these p38 MAP kinase homologs are not identical. For example, p38α induces apoptosis, whereas p38β induces hypertrophy of cardiomyocytes. 42) Further study is under way to determine what homologs of p38 MAP kinase are activated by various stimuli.
